Physician profile
Ari J Paley
NPI 1386834133
$13,628.49
in general payments reported to CMS, 2019-2025
40 companies · $2,387 in 2025
The $2,387 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,269 · 2020: $525 · 2021: $1,004 · 2022: $1,863 · 2023: $2,124 · 2024: $1,455 · 2025: $2,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,967.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,861.60 | 2019-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,157.95 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,122.37 | 2019-2025 | |
| Amgen INC. | $749.76 | 2019-2025 | Repatha, Repatha |
| Aop Health US, LLC | $612.29 | 2025 | Rapiblyk |
| Novo Nordisk INC | $547.53 | 2022-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $540.34 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $503.74 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $499.58 | 2019-2025 | Farxiga, Brilinta |
| Abbott Laboratories | $452.00 | 2019-2024 | Jot Dx |
| Janssen Pharmaceuticals, INC | $394.38 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $324.44 | 2023-2025 | Nexletol |
| Pfizer INC. | $324.40 | 2019-2025 | |
| Celgene Corporation | $307.79 | 2023-2025 | Camzyos |
| Scpharmaceuticals INC. | $206.15 | 2023-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Paley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.